Physician profile
Alex Ali Ehsan
NPI 1982883948
$24,518.55
in general payments reported to CMS, 2019-2025
55 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $21.23 · 2021: $172 · 2022: $24.96 · 2023: $2,302 · 2024: $4,749 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $8,438 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,200.00 |
| Food and Beverage | $8,438.29 |
| Education | $384.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $15,872.87 | 2024-2025 | Sancuso |
| Pfizer INC. | $821.88 | 2019-2025 | |
| Janssen Biotech, INC. | $653.36 | 2023-2025 | Erleada, Akeega, Balversa |
| Exelixis INC. | $602.41 | 2023-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $592.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $530.51 | 2023-2025 | |
| Astellas Pharma US INC | $441.67 | 2019-2025 | Xospata, Vyloy, Padcev |
| Abbvie INC. | $417.94 | 2023-2025 | |
| Genentech USA, INC. | $336.71 | 2023-2025 | Venclexta, Tecentriq, Tecentriq Hybreza |
| Incyte Corporation | $336.27 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $286.33 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.52 | 2022-2025 | Opdivo, Opdualag |
| Eisai INC. | $207.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.08 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Daiichi Sankyo INC. | $183.16 | 2023-2025 | Enhertu |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $164.66 | 2023-2025 | |
| Celgene Corporation | $154.50 | 2023-2025 | Reblozyl, Pomalyst |
| Array Biopharma INC | $147.50 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $131.38 | 2023-2025 | Padcev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.49 | 2023-2025 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $121.24 | 2023-2025 | Libtayo |
| Janssen Pharmaceuticals, INC | $117.00 | 2021 | |
| Gilead Sciences, INC. | $112.11 | 2019-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $110.32 | 2023-2024 | Besremi |
| Taiho Oncology, INC. | $109.12 | 2023-2025 | |
| Lilly USA, LLC | $107.19 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $100.68 | 2023-2025 | Iclusig, Fruzaqla, Alunbrig |
| Adc Therapeutics America, INC. | $97.59 | 2023-2025 | |
| Emd Serono, INC. | $91.43 | 2023-2025 | Bavencio |
| Karyopharm Therapeutics INC. | $89.40 | 2024-2025 | Xpovio |
| Sun Pharmaceutical Industries INC. | $81.91 | 2024-2025 | |
| Stemline Therapeutics INC. | $65.09 | 2023-2025 | Orserdu |
| Dendreon Pharmaceuticals LLC | $58.68 | 2025 | Provenge |
| Acrotech Biopharma INC. | $57.63 | 2021-2025 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $56.67 | 2024-2025 | |
| Puma Biotechnology, INC. | $53.09 | 2025 | |
| Ge Healthcare | $51.67 | 2025 | |
| Beone Medicines USA, INC. | $50.99 | 2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $50.86 | 2024 | Orgovyx |
| Springworks Therapeutics, INC. | $47.39 | 2024 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $45.66 | 2023-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $45.20 | 2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $43.99 | 2023-2025 | |
| G1 Therapeutics, INC. | $38.29 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $32.24 | 2025 | Danziten |
| Verity Pharmaceuticals INC. | $31.87 | 2025 | Trelstar |
| Apellis Pharmaceuticals, INC. | $24.99 | 2024 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $23.72 | 2023 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $23.48 | 2023 | Monoferric |
| Syndax Pharmaceuticals, INC. | $23.46 | 2025 | |
| Coherus Oncology, INC. | $21.87 | 2024 | |
| Deciphera Pharmaceuticals INC. | $17.29 | 2023 | Qinlock |
| Mirati Therapeutics, INC. | $16.10 | 2023 | Krazati |
| Agios Pharmaceuticals, INC. | $14.89 | 2023 | Pyrukynd |
| Verastem, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Ehsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.